Difluprednate Eye Prep

Difluprednate is a topical steroid that works by stopping the release of certain natural substances in the eye that are responsible for pain and inflammation. Corticosteroids inhibit the inflammatory response to a variety of inciting agents and may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

• Post-operative eye pain and inflammation
• Uveitis
• Pseudophakic cystoid macular edema (CME)
• Blepharitis and corneal inflammation

Corticosteroids inhibit the inflammatory response to a variety of inciting agents and may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

Difluprednate induces phospholipase A2 inhibitory proteins, reducing arachidonic acid release, which decreases production of inflammatory mediators such as prostaglandins and leukotrienes, thereby reducing ocular inflammation.

Post-operative inflammation & pain: 1 drop 4 times daily for 2 weeks starting 24 hours post-op; then 2 times daily for 1 week; then taper based on response.
Uveitis: 1 drop 4 times daily for 14 days; then taper as clinically indicated.
Blepharitis: 1 drop 2 times daily for 1 week, then once daily for 1 week.
Pseudophakic CME: 1 drop 2 times daily.

For ophthalmic use only. Shake well before use. Hold the dropper close to the eye without touching it. Place the medicine inside the lower eyelid. Apply pressure on the corner of the eye (close to the nose) for 1 minute immediately after instilling.

If you miss a dose, apply it as soon as possible. However, if it is almost time for your next application, skip the missed dose.

Common: Eye irritation, burning sensation, watery eyes, corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, blepharitis.
Serious: Elevated intraocular pressure (glaucoma), optic nerve damage, posterior subcapsular cataract formation, secondary ocular infection, corneal perforation.

Prolonged use may result in glaucoma and cataract formation; monitor IOP if used for 10 days or longer. Caution in patients with history of herpes simplex. Do not touch dropper tip to any surface.

Active viral diseases of the cornea and conjunctiva including herpes simplex keratitis, vaccinia, and varicella; mycobacterial infection of the eye; fungal diseases of ocular structures.

Specific drug interaction studies have not been conducted with Difluprednate 0.05% ophthalmic emulsion.

Can be used with or without food.

Pregnancy Category C. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

It is not known whether Difluprednate passes into breast milk; caution is required.

Pediatric patients were evaluated for inflammation following cataract surgery with a similar safety profile.

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

No special precautions are necessary for patients with kidney or liver problems.

Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.

Store at room temperature, protect from light and freezing.

Difluprednate Eye Prep